Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional...
Overview
Authors
Affiliations
Background: We aimed to quantify the unknown losses in health-related quality of life of coronavirus disease 2019 (COVID-19) cases using quality-adjusted lifedays (QALDs) and the recommended EQ-5D instrument in England.
Methods: Prospective cohort study of nonhospitalized, polymerase chain reaction (PCR)-confirmed severe acute respiratory syndrome coronavirus 2-positive (SARS-CoV-2-positive) cases aged 12-85 years and followed up for 6 months from 1 December 2020, with cross-sectional comparison to SARS-CoV-2-negative controls. Main outcomes were QALD losses; physical symptoms; and COVID-19-related private expenditures. We analyzed results using multivariable regressions with post hoc weighting by age and sex, and conditional logistic regressions for the association of each symptom and EQ-5D limitation on cases and controls.
Results: Of 548 cases (mean age 41.1 years; 61.5% female), 16.8% reported physical symptoms at month 6 (most frequently extreme tiredness, headache, loss of taste and/or smell, and shortness of breath). Cases reported more limitations with doing usual activities than controls. Almost half of cases spent a mean of £18.1 on nonprescription drugs (median: £10.0), and 52.7% missed work or school for a mean of 12 days (median: 10). On average, all cases lost 13.7 (95% confidence interval [CI]: 9.7, 17.7) QALDs, whereas those reporting symptoms at month 6 lost 32.9 (95% CI: 24.5, 37.6) QALDs. Losses also increased with older age. Cumulatively, the health loss from morbidity contributes at least 18% of the total COVID-19-related disease burden in the England.
Conclusions: One in 6 cases report ongoing symptoms at 6 months, and 10% report prolonged loss of function compared to pre-COVID-19 baselines. A marked health burden was observed among older COVID-19 cases and those with persistent physical symptoms.
Pritchard C, Kutikova L, Pitman R, Lai K, Beyhaghi H, Gibbons I Vaccines (Basel). 2025; 13(2).
PMID: 40006733 PMC: 11861217. DOI: 10.3390/vaccines13020187.
Vergouwe M, Birnie E, van Veelen S, Biemond J, Appelman B, Peters-Sengers H Open Forum Infect Dis. 2025; 12(2):ofaf055.
PMID: 39974282 PMC: 11837172. DOI: 10.1093/ofid/ofaf055.
Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands.
Zeevat F, van der Pol S, Westra T, Beck E, Postma M, Boersma C Adv Ther. 2025; 42(3):1550-1569.
PMID: 39928242 DOI: 10.1007/s12325-025-03112-y.
Tsuruoka M, Huynh M, Toizumi M, Hoang T, Nguyen T, Dao A Trop Med Health. 2025; 53(1):6.
PMID: 39810272 PMC: 11731347. DOI: 10.1186/s41182-024-00670-9.
Menkir T, Citarella B, Sigfrid L, Doshi Y, Reyes L, Calvache J medRxiv. 2024; .
PMID: 39040190 PMC: 11261939. DOI: 10.1101/2024.02.21.24303099.